Amneal Pharmaceuticals, Inc. — Form SCHEDULE 13D/A
Filed August 12, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 15/100
What the filing says
This is an amended Schedule 13D/A filing dated August 12, 2026, regarding beneficial ownership in Amneal Pharmaceuticals (market cap ~$1.7B). The filing header and metadata are present, but the actual amendment content—including counterparty identity, share counts, percentage holdings, or what changed from the original 13D—is not included in the provided text excerpt. Chintu Patel is listed as the filer.
Why this rating
Without substantive disclosure of holdings, changes, or transaction terms, cannot assess materiality. Routine procedural amendment; content required to judge impact is missing.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.